Document is current
Any future updates will be listed below
-
Authors
Villette, Claire C.
Dupuy, Nathalie
Brightman, Frances A.
Zimmermann, Astrid
Lignet, Floriane
Zenke, Frank T.
Terranova, Nadia
Bolleddula, Jayaprakasam
El Bawab, Samer
Chassagnole, Christophe https://orcid.org/0000-0002-3764-9407
-
Funding
Funding for this research was provided by:
Merck KGaA (CrossRef Funder ID: 10.13039/100009945, CrossRef Funder ID: 10.13039/100009945, CrossRef Funder ID: 10.13039/100009945, CrossRef Funder ID: 10.13039/100009945)
- License Information
-
More Information
Article History
Received: 19 January 2024
Revised: 4 December 2024
Accepted: 17 December 2024
First Online: 28 January 2025
Competing interests
: CV, FB, ND and CC are or have been employees and shareholders of Physiomics. AZ, FL, FZ, NT, JB, SEB are or have been employees and shareholder of the healthcare business of Merck KGaA, Darmstadt, Germany, Merck Institute for Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, or EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, and/or its affiliates have certain rights in patents, patent applications pertaining to gartisertib/M4344 (WO14089379). However, none of the authors are named inventors.
: All in vivo experiments were performed by XenTech (Evry, France) in accordance with French legislation concerning the protection of laboratory animals and in accordance with a license approved by the French Ministry of Higher Education, Research and Innovation (registration numbers APAFIS#7125-2016012713169445v3, APAFIS#11191v2; APAFIS#19620-2019021311503803v1).
